A New York City federal court has dismissed a proposed class-action lawsuit against Bristol Myers Squibb that accused the ...

By Jonathan Stempel NEW YORK (Reuters) -Bristol Myers Squibb won the dismissal of a proposed class action accusing it of ...

Celgene has today confirmed that it will acquire Juno Therapeutics for $9 billion, and says the move will make it a leader in cell immunotherapy. The price is a significant premium on the $5.5 bn ...

Celgene is to file its potential multiple sclerosis blockbuster ozanimod by the end of the year following phase 3 results showing it outperformed established injectable Avonex. Ozanimod was ...

A federal court in New York has reportedly dismissed a $6.4B suit against Bristol Myers Squibb (NYSE:BMY) that alleged the drugmaker wronged holders of Celgene contingency value rights by delaying ...

Celgene has acquired Gloucester Pharmaceuticals for US$340 million upfront and up to $300 million in milestones. Through the deal, Celgene gains Gloucester's romidepsin (Istodax), a histone ...

Celgene (Warren, NJ), a developer of chirally pure drugs, agreed on June 30 to purchase gene-regulation firm Signal Pharmaceuticals (San Diego, CA) for $200 million in an all-stock deal.

A federal judge in New York has dismissed a proposed class action against pharmaceutical giant Bristol Myers Squibb, which ...